ANI PHARMACEUTICALS, INC
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $78.3M | $-18.5M | $18.8M | $-47.9M | $-42.6M | $-22.5M | $6.1M | $15.5M |
| Depreciation & Amortization | $91.4M | $67.7M | $59.8M | $57.0M | $47.3M | $44.6M | $44.6M | $33.7M |
| Depreciation | $8.9M | $7.4M | $7.5M | $7.4M | $5.5M | $4.8M | $4.4M | $2.1M |
| Amortization | $82.5M | $60.3M | $52.3M | $49.5M | $41.8M | $39.9M | $40.2M | $31.7M |
| Stock-Based Compensation | $37.9M | $29.3M | $20.7M | $14.6M | $10.5M | $12.9M | $9.2M | $6.8M |
| Net Cash from Operating Activities | $185.2M | $64.0M | $119.0M | $-31.2M | $3.3M | $15.3M | $45.6M | $67.1M |
| Investing Activities | ||||||||
| Capital Expenditures | $13.8M | $16.2M | $8.9M | $8.9M | $2.6M | $6.1M | $6.6M | $5.7M |
| Business Acquisitions | — | — | $0 | $33.0K | $84.5M | $0 | $0 | $16.5M |
| Net Cash from Investing Activities | $-34.3M | $-404.7M | $-18.5M | $-15.7M | $-105.5M | $-68.3M | $-27.5M | $-27.4M |
| Financing Activities | ||||||||
| Dividends Paid | $1.2M | $1.6M | $1.6M | $1.6M | $190.0K | $0 | $0 | — |
| Stock Repurchases | $12.2M | $11.0M | $5.0M | $2.0M | $890.0K | $1.5M | $1.0M | $0 |
| Net Cash from Financing Activities | $-9.9M | $264.9M | $67.4M | $-5.1M | $194.6M | $-1.4M | $1.3M | $-27.8M |
| Net Change in Cash | $140.7M | $-76.2M | $167.9M | $-52.1M | $92.4M | — | — | — |
| Free Cash Flow | $171.4M | $47.8M | $110.1M | $-40.1M | $765.0K | $9.1M | $39.0M | $61.3M |